Since MutL− ER+/HER2− tumors have higher mutation load than MutL+ tumors13,17, we tested whether HER2 activation in these tumors occurs via activating mutations in HER2, a previously established mechanism of HER2 activation in HER2 non-amplified cancer cells7. Here, ESR1 is linked to cancer.